[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Free Fatty Acid Receptor 1 - Pipeline Review, H2 2019

December 2019 | 69 pages | ID: F60EDAB6E2CDEN
Global Markets Direct

US$ 3,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Free Fatty Acid Receptor 1 - Pipeline Review, H2 2019

SUMMARY

According to the recently published report 'Free Fatty Acid Receptor 1 - Pipeline Review, H2 2019'; Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) pipeline Target constitutes close to 17 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes.

Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Free fatty acid receptor 1 (FFA1), also known as GPR40, is a class A G-protein coupled receptor that is encoded by the FFAR1 gene. It is strongly expressed in the pancreatic islet cells and to a lesser extent in the brain. This membrane protein binds free fatty acids, acting as a nutrient sensor for regulating energy homeostasis.

The report 'Free Fatty Acid Receptor 1 - Pipeline Review, H2 2019' outlays comprehensive information on the Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase I and Preclinical stages are 1, 2 and 10 respectively. Similarly, the universities portfolio in Preclinical stages comprises 4 molecules, respectively. Report covers products from therapy areas Metabolic Disorders, Gastrointestinal, Cardiovascular, Genetic Disorders, Genito Urinary System And Sex Hormones, Infectious Disease, Musculoskeletal Disorders, Oncology and Respiratory which include indications Type 2 Diabetes, Diabetes, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Obesity, Acute Lung Injury, Acute Renal Failure (ARF) (Acute Kidney Injury), Chronic Kidney Disease (Chronic Renal Failure), Diabetic Nephropathy, Fibrosis, Hepatitis B, Idiopathic Pulmonary Fibrosis, Liver Cancer, Liver Fibrosis and Myocardial Fibrosis.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)
  • The report reviews Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) targeted therapeutics
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Overview
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Companies Involved in Therapeutics Development
Amgen Inc
Cadila Healthcare Ltd
Caldan Therapeutics Ltd
Daiichi Sankyo Co Ltd
Hyundai Pharmaceutical Co Ltd
Johnson & Johnson
Liminal BioSciences Inc
Merck & Co Inc
Scohia Pharma Inc
Takeda Pharmaceutical Co Ltd
TiumBio Co Ltd
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Drug Profiles
AM-3189 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DS-1558 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fasiglifam - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HOB-047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MK-2305 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NCE-406 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBI-4050 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBI-4547 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SCO-267 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize FFAR1 and PPARG for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR40 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize GPR40 for Type 2 Diabetes Mellitus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize GPR40 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize PPAR Gamma and GPR40 for Diabetes - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TUG-770 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZYDG-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Dormant Products
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Discontinued Products
Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) - Product Development Milestones
Featured News & Press Releases
Nov 18, 2019: Liminal presents new preclinical data on PBI-4050 and its effect on Angio-Proliferative Pulmonary Arterial Hypertension
Nov 12, 2019: Liminal BioSciences presents new preclinical data on PBI-4050
Nov 12, 2019: Liminal BioSciences presents new preclinical data on NASH candidate PBI-4547
Nov 11, 2019: Liminal Biosciences presents new preclinical data on PBI-4050 at ASN Kidney Week 2019
Oct 25, 2019: Liminal BioSciences announces upcoming presentation on its liver disease drug candidate PBI-4050 at The Liver Meeting 2019
Oct 25, 2019: Liminal BioSciences announces presentation on its liver disease drug candidate PBI-4547 at The Liver Meeting 2019
Oct 24, 2019: Liminal BioSciences announces upcoming presentation on drug candidate PBI-4050 at ASN kidney week 2019
Sep 09, 2019: Prometic reports first subject dosed in phase I clinical study with single ascending doses of PBI-4547
Jun 14, 2019: Prometic presents new data on PBI-4050 and its mechanism of action on kidney fibrosis at the 56th ERA/EDTA Congress
Jun 11, 2019: Publication regarding a preclinical study of SCO-267, a novel GPR40 agonist
Jun 05, 2019: SCOHIA PHARMA to present new preclinical data of SCO267, a GPR40 agonist, at The American Diabetes Association's 79th Scientific Sessions
May 22, 2019: Prometic presents new PBI-4050 data on lung fibrosis at the 2019 ATS Conference
Dec 05, 2018: Prometic to initiate PBI-4050 pivotal phase 3 clinical trial in Alstrom Syndrome
Aug 10, 2018: Prometic announces the publication of PBI-4050's antifibrotic activity in liver diseases in journal of pharmacology and experimental therapeutics
Aug 07, 2018: Prometic receives rare pediatric disease designation from U.S. FDA for small molecule drug candidate PBI-4050
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by Cadila Healthcare Ltd, H2 2019
Pipeline by Caldan Therapeutics Ltd, H2 2019
Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2019
Pipeline by Johnson & Johnson, H2 2019
Pipeline by Liminal BioSciences Inc, H2 2019
Pipeline by Merck & Co Inc, H2 2019
Pipeline by Scohia Pharma Inc, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Pipeline by TiumBio Co Ltd, H2 2019
Dormant Projects, H2 2019
Discontinued Products, H2 2019

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019

COMPANIES MENTIONED

Amgen Inc
Cadila Healthcare Ltd
Caldan Therapeutics Ltd
Daiichi Sankyo Co Ltd
Hyundai Pharmaceutical Co Ltd
Johnson & Johnson
Liminal BioSciences Inc
Merck & Co Inc
Scohia Pharma Inc
Takeda Pharmaceutical Co Ltd
TiumBio Co Ltd


More Publications